Molecular action of methotrexate in inflammatory diseases

Arthritis Research

Volumn 4, Issue 4, 2002, Pages 266-273

  Chan, Edwin S L ^a   Cronstein, Bruce N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine receptor; Arthritis; Inflammation; Methotrexate; Rheumatoid

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT; BIOLOGICAL RESPONSE MODIFIER; CAFFEINE; METHOTREXATE; NUCLEOSIDE;

ANTIINFLAMMATORY ACTIVITY; CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NONHUMAN; PURINE SYNTHESIS; PYRIMIDINE SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS;

ADENOSINE; ANIMAL; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN; HUMANS; METHOTREXATE; RECEPTORS, PURINERGIC P1; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0035985787     PISSN: 14659905     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar419     Document Type: Review

References (101)

1. Efficacy of low-dose methotrexate in rheumatoid arthritis
2. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
3. Polyglutamation of methotrexate. Is methotrexate a prodrug?
4. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5-adenylate deaminase by polyglutamates of mathotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide
5. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates
6. Clinical Pharmacology of Cancer Chemotherapy
7. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis
8. Methotrexate for rheumatoid arthritis
9. Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis
10. Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis
11. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention
12. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials
13. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study
14. The use of folates concomitantly with low-dose pulse methotrexate
15. Folic acid and methotrexate in rheumatoid arthritis
16. Folic acid and methotrexate in rheumatoid arthritis
17. Folic acid and methotrexate in rheumatoid arthritis
18. Folate supplementation and methotrexate
19. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled study
20. Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. An update and proposals for guidelines
21. Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport
22. 4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate
23. Activation of leukotriene synthesis in human neutrophils by exogenous arachidonic acid: Inhibition by adenosine A[2a] receptor agonists and crucial role of autocrine activation by leukotriene B[4]
24. Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells
25. Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis
26. Regulation of IL-2 production by mononuclear cells from rheumatoid arthritis synovial fluids
27. Polyamine levels in synovial tissues and synovial fluids of patients with rheumatoid arthritis
28. Levels of urinary polyamines in patients with rheumatoid arthritis
29. In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients
30. The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine
31. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells
32. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside: Effects on flow, granulocytes and injury
33. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate
34. The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion
35. Aminoimidazole carboxamide excretion in vitamin B12 and folic acid deficiencies
36. The antiinflammatory mechanism of methotrexate: Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation
37. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′ nucleotidase-mediated conversion of adenine nucleotides
38. Potentiation of leukotriene B4-mediated inflammatory response by the adenosine antagonist, 8-phenyl theophylline
39. Purinergic regulation of bradykinin-induced plasma extravasation and adjuvant-induced arthritis in the rat
40. Suppression of macrophage inflammatory protein [MIP]-1alpha production and collagen-induced arthritis by adenosine receptor agonists
41. The effects of caffeine ingestion on the efficacy of methotrexate
42. Oxidants, inflammation, and anti-inflammatory drugs
43. Adenosine: A physiological modulator of superoxide anion generation by human neutrophils
44. A new physiological function for adenosine: Regulation of superoxide anion production
45. Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils
46. Occupancy of G alpha s-linked receptors uncouples chemoattractant receptors from their stimulus-transduction mechanisms in the neutrophil
47. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A[2A] receptor agonists
48. Adenosine: An endogenous inhibitor of neutrophil-mediated injury to endothelial cells
49. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors
50. Adenosine inhibits neutrophil vascular endothelial growth factor release and transendothelial migration via A2B receptor activation
51. Fcgamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy: A1 receptors are stimulatory and A2 receptors are inhibitory
52. Chemoattractant-induced release of elastase by tumor necrosis factor-primed human neutrophils: Auto-regulation by endogenous adenosine
53. Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor: The role of selectins
54. Acting via A2 receptors, adenosine inhibits the upregulation of Mac-1 [CD11b/CD18] expression on FMLP-stimulated neutrophils
55. Macrophages in rheumatoid arthritis
56. Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function
57. Dynamics of chemotactic peptide-induced superoxide generation by human monocytes
58. 1 receptor promotion of multinucleated giant cell formation by human monocytes: A mechanism for methotrexate-induced nodulosis in rheumatoid arthritis
59. 1 receptor promotion of multinucleated giant cell formation by human monocytes, a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis
60. Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis
61. Inhibition of LPS-induced TNF alpha production in human monocytes by adenosine [A2] receptor selective agonists
62. Inhibition of TNF-alpha expression by adenosine: Role of A3 adenosine receptors
63. Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha
64. Differential regulatory effects of adenosine on cytokine release by activated human monocytes
65. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice
66. 2A receptors in human monocytoid THP-1 cells
67. IFN-gamma up-regulates the A2B adenosine receptor expression in macrophages: A mechanism of macrophage deactivation
68. Neutrophil-derived 5′-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation
69. Adenosine prevents permeability increase in oxidant-injured endothelial monolayers
70. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells
71. Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells
72. Adenosine stimulates proliferation of human endothelial cells in culture
73. Stimulation of human umbilical vein endothelial cell proliferation by A2-adenosine and beta 2-adrenoceptors
74. Protein tyrosine phosphatase-dependent proteolysis of focal adhesion complexes in endothelial cell apoptosis
75. Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis
76. One year treatment with low dose methotrexate in rheumatoid arthritis: Effect on class specific rheumatoid factors
77. IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis
78. Associations of IgA and IgA-rheumatoid factor with disease features in patients with rheumatoid arthritis
79. Immunologic studies of rheumatoid arthritis patients treated with methotrexate
80. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells
81. Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis
82. Methotrexate inhibits rheumatoid synovitis by inducing apoptosis
83. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis
84. Expression of A2B adenosine receptors in human lymphocytes: Their role in T cell activation
85. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response
86. Anti-cytokine therapy in chronic destructive arthritis
87. Effect of antiarthritic drugs on the enhanced interleukin-1 [1L-1] production by macrophages from adjuvant-induced arthritic [AA] rats
88. Low dose methotrexate decreases intraarticular prostaglandin and interleukin 1 levels in antigen induced arthritis in rabbits
89. The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis
90. The effects of methotrexate on the production and activity of II-1
91. The effect of antirheumatic drugs on interleukin 1 [IL-1] activity and IL-1 and IL-1 inhibitor production by human monocytes
92. Mechanism of action of methotrexate: Experimental evidence that methotrexate blocks the binding of interleukin 1 beta to the interleukin 1 receptor on target cells
93. Methotrexate suppresses Nf-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation
94. Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor
95. Activation and methotrexate-mediated suppression of the TNF alpha promoter in T cells and macrophages
96. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis [CIA]: A mechanism for methotrexate-mediated immunosuppression
97. Tumour necrosis factor [TNF] production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis
98. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4
99. Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis
100. Relationship of soluble interleukin-2-receptor and interleukin-6 with class-specific rheumatoid factors during low-dose methotrexate treatment in rheumatoid arthritis
101. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: Evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive transcriptase-polymerase chain reaction